AvengeBio - Crunchbase Company Profile & Funding

Q: Who invested in AvengeBio?

AvengeBio has 5 investors including CAM Capital And Longitude Capital.

Q: When was the last funding round for AvengeBio?

AvengeBio closed its last funding round on obfuscated from a Series A round.

Q: How much funding has AvengeBio raised to date?

AvengeBio has raised obfuscated.

Overview

AvengeBio

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About AvengeBio

CB Rank

81613

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.

Founded

obfuscation

Private

Series A

Cambridge, Massachusetts, United States

11-50

avengebio.com/

Biotechnology

Health Care

Medical

Funding Rounds

Series A

OBF

obfuscation

Seed

OBF

obfuscation

Key People

Claudio Dansky Ullmann: Chief Medical Officer
Omid Veiseh: founder
Past Role: Sigilon Therapeutics, Co-Founder

Details

Legal Name

Avenge Bio, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Michael Heffernan, Michael T. Heffernan, Omid Veiseh, Paul Wotton, Paul Wotton

About the Company

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.

Contact Email

info@avengebio.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

LOCOcyte Platform

An allogeneic cell-based immunotherapy platform designed for localized modulation of the immune system, generating both local and systemic anti-tumor responses.

AVB-001

An encapsulated cell product engineered to produce native human interleukin-2 (hIL-2), delivered intraperitoneally to treat high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

Research & Development

AvengeBio is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A
obfuscated obfuscation	Series A - AvengeBio	5	obfuscated obfuscation	CAM Capital, Perceptive Advisors	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
CAM Capital	Yes	Series A - AvengeBio	Scott Morenstein
CAM Capital	Yes	Series A - AvengeBio	Scott Morenstein
CAM Capital	Yes	Series A - AvengeBio	Scott Morenstein
CAM Capital	Yes	Series A - AvengeBio	Scott Morenstein
CAM Capital	Yes	Series A - AvengeBio	Scott Morenstein